Read More

Kodiak Sciences Data At ARVO 2024 Highlight Depth Of Early And Late-Phase Retina Pipeline Including Advancements With High Drug-Antibody-Ratio Therapeutics Built On Kodiak’s Antibody Biopolymer Conjugate Platform

Tarcocimab clinical and non-clinical data highlight strong 6-month efficacy profile in diabetic retinopathy patients and continued favorable safety profile.KSI-501 clinical and non-clinical data highlight multiple

KOD

Read More

Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday’s Mid-Day Session

Shares of Kodiak Sciences Inc. (NASDAQ: KOD) fell sharply during Thursday’s session after the company reported a wider-than-expected fourth-quarter loss. Kodiak Sciences posted a quarterly loss of $1.13 per share, compared to market expectations for a loss of 77 cents per share.

ABTS

Read More

Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday’s Mid-Day Session

Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition.

AAGR